| Table 2. Donor oocyte cycles and embryo transfer characteristics. | |
| Variables | n=213 |
|---|---|
|
Oocyte source, n (%) Cryopreserved Fresh Fresh+ Cryopreserved |
32 (15.0) 180 (84.5) 1 (0.5) |
| GnRH (antagonist), n (%) | 42 (19.8) |
|
Endometrial preparation, n (%) Hormone replacement cycle Spontaneous cycle monitoring |
204 (97.1) 6 (2.9) |
| Endometrial thickness, median (IR) | 8 (7-9) |
|
Estrogen replacement, n (%) Oral constant dose Oral increasing dose Vaginal increasing dose |
120 (58.3) 85 (41.3) 1 (0.5) |
| Days on medication, median (IR) | 19 (17-21) |
|
Luteal phase, n (%) Vaginal Combined None Not available |
203 (96.2) 4 (1.9) 1 (0.5) 3 (1.4) |
|
Embryo cryopreservation stage, n (%) Blastocyst Cleaving Embryo Combined |
198 (93.0) 11 (5.2) 4 (1.9) |
|
Genetic diagnosis, n (%) PGT-A None |
41 (19.2) 172 (80.8) |
|
Number of embryos transferred, n (%) 1 2 |
156 (73.2) 57 (26.8) |
|
Classification of the best embryo, n (%) BL1 BL2 BL3 Cleaving embryos Morula |
144 (67.6) 55 (25.8) 2 (0.9) 8 (4.8) 1 (0.5) |
IR: interquartile range, PGT-A: preimplantation genetic testing for aneuploidies.